

KLİNİK ARAŞTIRMA

**THE EFFECT OF TERIPARATIDE THERAPY
ON REGULATORS OF BONE TURNOVER
AND QUALEFFO-41**

TERİPARATİD TEDAVİSİNİN KEMİK DÖNGÜSÜ DÜZENLEYİCİLERİ VE
QUALEFFO-41 ÜZERİNE ETKİSİ

Ece HARMAN¹
Korhan Barış BAYRAM²
Gökçen KOCABAŞ UNAL³
Serkan AKÇAY⁴
Serpil BAL²
Hüseyin CAN⁵
Hasan Kamil SUCU⁶

SUMMARY

Objective: The aim of this cross-sectional study was to compare the effects of teriparatide therapy on anabolic hormones and bone turnover markers and quality of life in patients with osteoporotic fractures.

Materials and methods:

Patients with severe osteoporosis defined as lumbar total T-score or femur neck T-score ≤ -4.0 and at least 2 lumbar vertebral compression fractures were enrolled. 15 patients were on teriparatide therapy and 15 patients had no therapy. ALP, osteocalcin, GH, IGF-1, IGFBP and SHBG levels were determined. QUALEFFO-41 was used for QOL evaluation.

Results: In the teriparatide group ALP and osteocalcin levels were significantly higher ($p < 0.05$). GH, IGF-1, IGFBP and SHBG levels did not differ significantly ($P > 0.05$). In teriparatide patients, physical function (a,b,c,d,e), general health evaluation (f) and total QUALEFFO-41 scores were significantly lower, while mental function (g) scores were significantly higher ($p < 0.05$). Physical function scores b and c were negatively correlated with IGF-1 ($p < 0.05$). Treatment duration in teriparatide group was negatively correlated with physical function scores a, b, c, d and general health score (f) ($p < 0.05$).

Conclusions: In this study teriparatide therapy was shown to raise the levels of bone turnover markers significantly and affect quality of life positively in osteoporotic patients with vertebral fractures and these improvements were correlated with treatment duration.

Key words: Osteoporosis, Growth Hormone, Teriparatide, Spinal Fractures

Department of Endocrinology and Metabolism (Spec. Dr. E. Harman)
Department of Physical Therapy and Rehabilitation (Assoc. Prof. Dr. S. Bal, Spec. Dr. K. B. Bayram)
Department of Orthopaedics & Traumatology (Spec. Dr. S. Akçay)
Department of Family Medicine (Assist. Prof. Dr. H. Can)
Department of Neurosurgery (Assoc. Prof. Dr. H. K. Sucu)
İzmir Katip Çelebi University Atatürk Training and Research Hospital, İzmir-TURKEY
Ege University Medical Faculty, Department of Endocrinology and Metabolism, İzmir (Spec. Dr. G. Kocabaş Ünal)
Corresponding Author: Ece Harman, MD

ÖZET

Amaç: Osteoporotik vertebral kırık nedeniyle teriparatid tedavisi alanlarda kemik döngüsü düzenleyicileri ile yaşam kalitesi parametrelerinin incelenmesi

Gereç ve Yöntem: Çalışmaya kemik mineral yoğunluğu (KMY) ölçüm değerlerine göre ileri osteoporotik (Total lomber omurga veya total femur bölgesi T skoru ≤ -4.0) ve en az iki vertebra kompresyon fraktürü olan olgular (Grup B, s=15, teriparatid alan / Grup A, s=15, tedavi almayan) alındı. Serum ALP, osteokalsin, BH, IBF-1, IBFBP-3 ve SHBG değerlendirildi. Yaşam kalitesi spesifik bir anket olan QUALEFFO-41 ile değerlendirildi.

Bulgular: Tedavi alan grupta alkalen fosfataz ve osteokalsin değerleri diğer gruba göre anlamlı yüksekti ($p < 0.05$). BH, IBF-1, IBFBP-3 ve SHBG açısından gruplar arasında anlamlı fark yoktu ($p > 0.05$). Tedavi alan grupta fiziksel fonksiyon (a,b,c,d,e), genel sağlık değerlendirmesi (f) ve toplam QUALEFFO puanları düşük ($p < 0.05$); zihinsel fonksiyon (g) değerlendirme puanı ise yüksek bulundu ($p < 0.05$). Tedavi alan grupta yaşam kalite indeksinde yeralan fiziksel fonksiyon "b" ve "c" skorları ile "IBF-1" arasında negatif korelasyon bulundu ($p < 0.05$). Tedavi alan olguların yaşam kalite indeksi skorları ile tedavi süresi incelendiğinde; fiziksel fonksiyon skoru "a,b,c,d" ve genel sağlık skoru "f" ile tedavi süresi arasında negatif korelasyon saptandı ($p < 0.05$).

Sonuç: Osteoporotik vertebral kırıklı olgularda teriparatid tedavisinin kemik formasyon belirteçlerinde artış sağladığı, yaşam kalitesini olumlu yönde etkilediği ve bu durumun tedavi süresiyle ilişkili olduğu saptanmıştır.

Anahtar Sözcükler: Osteoporoz, Büyüme Hormonu, Teriparatid, Spinal kırıklar

INTRODUCTION

Growth hormone (GH) and insulin-like growth factor-1 (IGF-1) are involved in lifelong process of regulating the balance between bone formation and resorption. While GH and IGF-1 affect prepubertal longitudinal bone growth, skeletal maturation and act to increase bone mass, in adults they play a role in maintaining existing bone mass by creating an anabolic effect on trabecular and cortical bones. With advancing age, reductions in growth hormone levels, physical performance and bone mineral density and an increase in body fat mass are observed in line with decreased growth hormone releasing hormone and increased somatostatin secretion. Systemic IGF-1 is synthesized primarily in the liver, depending on the growth hormone levels. Insulin-like growth factor binding proteins (IGFBPs) are involved in maintaining levels of freely circulating IGF-1 at 1% or less of the total amount. IGFBP-3 is the major component of circulating IGF complex and inhibits the action of IGF-1. GH also contributes to secretion of parathyroid hormone (PTH) by regulating activities of renal 1α -hydroxylase and 24-hydroxylase enzymes, conferring an indirect action on bone metabolism (1). PTH raises IGF-1 levels and helps cell proliferation. A significant correlation between bone mineral density and IGF-1 levels was shown in GH-deficient individuals and IGFBP-3 levels were found to be a prominent marker for IGFBP-3 in healthy individuals (2,3,4).

Sex hormone binding globulin (SHBG) is a plasma glycoprotein which regulates bioavailability of sex steroids including 5α -dihydrotestosterone, testosterone

and 17β -estradiol by binding these sex hormones with great affinity and SHBG was suggested as an indicator of cortical bone macroarchitecture (5). Osteocalcin is a bone-specific protein that is synthesized by non-collagenous osteoblasts found in the bone matrix. It is a marker for high bone turnover rate and reduced bone mineral density in correlation with histomorphometric structure of the bone. Similar to serum osteocalcin levels, serum alkaline phosphatase (ALP) activity is another useful diagnostic parameter which indicates bone formation and resorption.

In patients with severe osteoporosis whose response to anti-resorptive therapy is inadequate, new bone formation might be achieved by stimulating osteoblastic activation using a PTH analogue (teriparatide 1-34 rh PTH). PTH may exert its anabolic activity by regulating growth factors, IGF-1 and structures such as sclerostin, via an indirect action. However, the exact molecular mechanisms responsible for these activities have not yet been fully elucidated (6). In studies, it was shown that back pain subsided during teriparatide therapy and this improvement was maintained after discontinuation of medical therapy (7).

In this study, a cross-sectional assessment was planned in order to examine sociodemographic data (retrospectively) of patients who were receiving teriparatide treatment for an osteoporotic vertebral fracture and patients not on any treatment, to evaluate both study groups with respect to parameters including GH, IGF-1, IGFBP-3, SHBG, osteocalcin and ALP and to investigate effects of therapy and its duration on these parameters and quality of life.

MATERIALS AND METHODS

Sample Selection

The study enrolled female patients with established diagnosis of osteoporotic vertebral fracture who admitted to outpatient clinics of Department of Physical Therapy and Rehabilitation and Department of Endocrinology and Metabolism Disorders and did not receive any treatment for osteoporosis (Group A, n=15) and other female patients who were started on teriparatide therapy (Group B, n=15). Enrolled patients were fully informed about the purpose and method of the study and gave written informed consent. The study was approved by the local ethics committee. Subjects who had any thyroid, parathyroid, hepatic or renal disorders, inflammatory joint disease, history of malignancy, history of using medications known to affect bone metabolism and history of traumatic vertebral fractures were excluded from the study.

Bone Mineral Density Measurement

BMD measurements from lumbar spine and hip region of the dominant extremity (proximal femur) were obtained by using a DEXA instrument (Norland XR36, Norland Medical Systems Inc., Fort Atkinson, USA). Patients were positioned as instructed by the manufacturer with the aid of supplied accessories. Severely osteoporotic patients (total lumbar spine or total femur T-score ≤ -4.0) as evidenced by bone mineral density (BMD) results and those patients with at least two vertebral compression fractures were enrolled. A vertebral fracture was defined as 25% or less reduction in any measurements of anterior, medial and posterior height of the vertebra compared to adjacent one, as determined by lateral radiographies of thoracic and lumbar region.

Laboratory Measurements: Serum GH, IGF-1, IGFBP, PTH, SHBG and Osteocalcin levels were obtained by an Immulite 2000 autoanalyzer (Siemens Healthcare Diagnostics, Deerfield, IL, USA) using chemiluminescent method and commercial kits.

Questionnaire

A questionnaire for sociodemographic data (Appendix 1) was generated which included age, education level, body weight, height, menarche age, parturition number, pregnancy and lactation periods, age and duration of menopause, history of comorbid conditions, sedentary life style, family history of fractures, medication use, coffee, alcohol or smoking habits, dietary habits, consumption of calcium-rich food and amount ingested (milk, yogurt, cheese, fish, red meat). Also,

Quality of Life Questionnaire of the European Foundation for Osteoporosis (QUALEFFO-41) was administered (Appendix 2) (8). QUALEFFO-41 was used in the evaluation of quality of life, which is a specific questionnaire. This questionnaire contains a total of 41 questions under 7 subsections of pain, daily living activities, household chores, mobility (these three are found under "physical functions" heading), social activity, general health evaluation and mental function. Score for each subscale was found by adding scores from questions of subscales and converting the sum into a 0-100 point scale. Total QUALEFFO-41 was obtained by adding scores from all questions and converting the sum into a 0-100 point scale (9). In this scale, 0 point indicates "best" and 100 points indicates "worst" condition for each subscale and total.

Data Analysis: Statistical analysis of data was performed using SPSS 15.0 for Windows software package with 95% confidence. Chi-Square and Fisher's Exact tests were used for within-group comparisons of categorical variables and Mann Whitney U test for between-group comparisons of continuous variables. Pearson and Spearman correlation statistics was used for analysis of correlation between variables. A p value below 0.05 was considered significant.

RESULTS

Mean age of patients treated by teriparatide for osteoporotic vertebral fractures (Group B) was $78,8 \pm 4,25$ (years) and mean age of non-treated patients (Group A) was $76,47 \pm 5,33$ (years). Age, body weight, height, duration of menopause, parturition number, lactation period, dietary habits (smoking, alcohol, coffee consumption, calcium intake), life style (active/sedentary) were similar in both groups.

Comparison of both groups with respect to laboratory parameters revealed statistically significantly higher ALP and osteocalcin values in the treatment group versus non-treated group ($p < 0,05$). GH, IGF-1, IGF-BP and SHBG values did not differ statistically significantly in both groups ($p > 0,05$). Breakdown of laboratory parameters by patient groups is given in Table 1.

For the evaluation of quality of life, scores for pain, daily living activities, household chores, mobility, social activities, general health evaluation and total QUALEFFO score were statistically significantly lower in the treatment group compared to non-treated group ($p < 0,05$), whereas mental function evaluation score was statistically significantly higher in the treatment group ($p < 0,05$) compared to non-treated group.

Table 1. Kemik döngüsü düzenleyicilerin hasta gruplarına göre dağılımı

	Grup A (s=15)	Grup B (s=15)	Toplam (s=30)	P değeri
ALP	70,13±49,80	85,80±35,47	77,97±43,22	0,016
Osteokalsin	2,16±0,47	4,33±2,30	3,25±1,97	0,001
BH	1,23±1,14	1,99±2,14	1,61±1,73	> 0,05
IGF-1	108,95±55,38	115,75±62,18	112,35±57,96	> 0,05
IGFBP-3	17,63±27,73	36,73±109,95	27,18±79,38	> 0,05
SHBG	72,57±37,77	68,75±27,70	70,66±32,6	> 0,05

Table 2. Breakdown of bone turnover regulators by patient groups.

	Group A (n=15)	Group B (n=15)	Total (n=30)	p value
ALP	70.13±49.80	85.80±35.47	77.97±43.22	0.016
Osteocalcin	2.16±0.47	4.33±2.30	3.25±1.97	0.001
GH	1.23±1.14	1.99±2.14	1.61±1.73	>0.05
IGF-1	108.95±55.38	115.75±62.18	112.35±57.96	>0.05
IGFBP-3	17.63±27.73	36.73±109.95	27.18±79.38	>0.05
SHBG	72.57±37.77	68.75±27.70	70.66±32.6	>0.05

Assessment of laboratory values and parameters for quality of life index showed a negative correlation between scores of daily living activities and household chores in the quality of life questionnaire and "IGF-1" among treated patients ($p<0,05$).

When the association between scores for quality of life index and duration of therapy was examined by the treatment group, negative correlations were found between duration of therapy and scores for pain, daily living activities, household chores, mobility, general health evaluation ($p<0,05$). There was not any correlation between laboratory parameters among treated patients.

DISCUSSION

Growth hormone and IGF-1 play an important role in the bone metabolism and lead to increased bone fragility and osteoporosis risk in parallel with suppression of GH/IGF-1 axis with advancing age (10). IGF-1 has a potent stimulatory effect on proliferation of osteoblasts and synthesis of bone-specific proteins in cell culture (11,12). Bone mineral density was decreased compared to normal subjects and circulating IGF-1 levels correlated with bone mineral density in GH-deficient individuals (2,3). IGFBP-3 is the major component of circulating IGF complex and inhibits the action of IGF-1. In one study, decreased levels of IGFBP-3 were found among patients with osteoporosis compared to healthy subjects but GH and IGF-1 levels were similar in both groups (13). In another study; IGFBP-3 levels were found to contribute to variations

in bone mineral density among healthy subjects and IGF-1 and IGFBP-3 were significantly lower in osteoporotic patients compared to healthy individuals (14).

ALP and osteocalcin are important markers of bone resorption and formation. Osteocalcin is a product of osteoblasts. Studies have shown significantly higher ALP and osteocalcin levels among osteoporotic women compared to non-osteoporotic women (15). This increase was apparent within the first 5 years after the onset of menopause and represents increased bone turnover.

SHBG has a key role in bone loss. It is the main predictor of vertebral and peripheral (particularly proximal femur) bone fractures. An inverse correlation was shown between bone mineral density and SHBG levels among males and females. A weak association was found between SHBG levels and markers of bone turnover (5). IGF-1 levels were reported to show a strong negative correlation with SHBG (16). SHBG showed a moderate correlation with the markers of bone resorption and a weak correlation with markers of bone formation (particularly osteocalcin) (17).

Teriparatide (1-34 rhPTH), a PTH analogue, is an anabolic agent which helps formation of new bone tissue via a stimulatory effect on osteoblasts. PTH inhibits apoptosis of osteoblasts and increases IGF-1 synthesis independent of GH. IGF-1 has strong anabolic effects on the bones (18). IGF-1 levels were shown not to increase following 24-hour PTH infusion but significant increases were seen in IGFBP-3 levels

among healthy female subjects (19). Moreover, in studies, C-terminal of PTH was reported to increase apoptosis of osteocytes and stimulate ALP and other markers of osteoblastic activity (20). At least 75% increase in bone levels of ALP and osteocalcin was reported after completion of teriparatide therapy (21). Also, there are results showing improvements in parameters of quality of life, relief of pain symptoms and elimination of emotional disorders and fear of fall (22). One study reported that fracture risk and back pain diminished during 18 months of teriparatide therapy and these improvements were sustained after discontinuation of therapy (7).

In this study, we found significantly increased serum osteocalcin and ALP levels among treated patients. When results were analyzed according to duration of treatment (0-6 months / 6-12 months / 12-18 months), significantly low scores for pain and general health evaluation in the quality of life questionnaire and significantly decreased SHBG levels were observed in patients treated for a period of 12 to 18 months. This was considered to result from anabolic action of teriparatide therapy. Ultimately, accelerated bone formation and fracture improvement lead to diminished pain and positive effects on general health. Specifically, impaired posture after a fracture results in advancement of pain to chronic state and disruption of physical, social and mental functions. In their study, Panico et al. (23) demonstrated significant improvements in all parameters of the quality of life index-QUALEFFO scale with teriparatide therapy due to increased levels of ALP (a marker of bone turnover) and mainly in pain. In a study conducted by Maugeri et al. (24), the efficacy of teriparatide therapy was investigated among osteoporotic subjects with severe fractures and significant improvements were observed particularly at the end of 18 months in all parameters of the quality of life index- QUALEFFO scale, which were maintained up to 24 months. Manuele et al. (25) stated that teriparatide therapy is an effective therapeutic option for osteoporotic patients with severe fractures who are refractory to other treatments and showed positive effects mainly on pain and physical function and all other indicators of quality of life.

As an extension to our study, regulators of bone turnover and contribution of these markers to prognosis may be evaluated also in patients treated with antiresorptive agents. With increased life expectancy and greater number of cases seen among geriatric patients with osteoporotic vertebral fractures, there is a need to

consider treatment cost as well as treatment efficacy in the therapeutic decision making.

Abbreviations: ALP (Serum alkaline phosphatase), GH (Growth Hormone), IGF-1 (Insulin-like growth factor-1), IGFBP (Insulin-like growth factor binding protein), BMD (Bone mineral density), PTH (Parathyroid hormone), SHBG (Sex hormone binding globulin), QUALEFFO-41 (Quality of life questionnaire of the European Foundation for Osteoporosis).

REFERENCES

1. Wei S, Tanaka H, Kubo T, Ono T, Kanzaki S, Seino Y. Growth hormone increases serum 1,25-dihydroxyvitamin D levels and decreases 24,25-dihydroxyvitamin D levels in children with growth hormone deficiency. *Eur J Endocrinol*. 1997 Jan;136(1):45-51. PMID:9037126.
2. Johansson AG, Burman P, Westermark K, Ljunghall S. The bone mineral density in acquired growth hormone deficiency correlates with circulating levels of insulin-like growth factor I. *J Intern Med*. 1992 Nov;232(5):447-52. PMID:1453131.
3. Holmes SJ, Economou G, Whitehouse RW, Adams JE, Shalet SM. Reduced bone mineral density in patients with adult onset growth hormone deficiency. *J Clin Endocrinol Metab*. 1994 Mar;78(3):669-74. PMID:8126140.
4. Johansson AG, Forslund A, Hambraeus L, Blum WF, Ljunghall S. Growth hormone-dependent insulin-like growth factor binding protein is a major determinant of bone mineral density in healthy men. *J Bone Miner Res*. 1994 Jun;9(6):915-21. PMID: 7521562.
5. Hoppé E, Bouvard B, Royer M, Audran M, Legrand E. Sex hormone-binding globulin in osteoporosis. *Joint Bone Spine*. 2010 Jul;77(4):306-12. PMID: 20452803.
6. Misiorowski W. [Parathyroid hormone and its analogues - molecular mechanisms of action and efficacy of osteoporosis therapy]. *Endokrynol Pol*. 2011;62 Suppl 2:32-6. Polish. PMID:22125020.
7. Fahrleitner-Pammer A, Langdahl BL, Marin F, Jakob F, Karas D, Barrett AL, Junggren Ö, Walsh JB, Rajzbaum G, Barker C, Lems WF. Fracture rate and back pain during and after discontinuation of teriparatide: 36-month data from the European Forsteo Observational Study (EFOS). *Osteoporos Int*. 2011 Oct;22(10):2709-19.
8. Lips P, Cooper C, Agnusdei D, Caullin F, Egger P, Johnell O, Kanis JA, Kellingray S, Leplege A, Liberman UA, McCloskey E, Minne H, Reeve J, Reginster JY, Scholz M, Todd C, de Vernejoul MC, Wiklund I. Quality of life in patients with vertebral fractures: validation of the Quality of Life Questionnaire of the European Foundation for Osteoporosis (QUALEFFO). Working Party for Quality of Life of the European Foundation for Osteoporosis. *Osteoporos Int*. 1999;10(2):150-60.
9. Koçyigit H, Gülseren S, Erol A, Hizli N, Memis A. The reliability and validity of the Turkish version of Quality of Life Questionnaire of the European Foundation for Osteoporosis (QUALEFFO). *Clin Rheumatol* 2003 Feb; 22(1): 18-23. PMID: 12605312.
10. Agnusdei D, Gentilella R. GH and IGF-I as therapeutic agents for osteoporosis. *J Endocrinol Invest*. 2005;28(8 Suppl):32-6. Review. PubMed PMID: 16323827.

11. Hock JM, Centrella M, Canalis E. Insulin-like growth factor I has independent effects on bone matrix formation and cell replication. *Endocrinology*. 1988 Jan;122(1):254-60. PMID: 3335207.
12. Schmid C. The regulation of osteoblast function by hormones and cytokines with special reference to insulin-like growth factors and their binding proteins. *J Intern Med*. 1993 Dec;234(6):535-42. PMID:7505030.
13. Johansson AG, Eriksen EF, Lindh E, Langdahl B, Blum WF, Lindahl A, Ljunggren O, Ljunghall S. Reduced serum levels of the growth hormone-dependent insulin-like growth factor binding protein and a negative bone balance at the level of individual remodeling units in idiopathic osteoporosis in men. *J Clin Endocrinol Metab*. 1997 Sep;82(9):2795-8.
14. Wüster C, Blum WF, Schlemilch S, Ranke MB, Ziegler R. Decreased serum levels of insulin-like growth factors and IGF binding protein 3 in osteoporosis. *J Intern Med*. 1993 Sep;234(3):249-55. PMID:7689089.
15. Atalay S, Eloi A, Kayadibi H, Onder CB, Aka N. Diagnostic utility of osteocalcin, undercarboxylated osteocalcin, and alkaline phosphatase for osteoporosis in premenopausal and postmenopausal women. *Ann Lab Med*. 2012 Jan;32(1):23-30. Epub 2011 Dec 20. PubMed PMID: 22259775; PubMed Central PMCID:PMC3255495.
16. Gomez JM, Maravall FJ, Gomez N, Navarro MA, Soler J. Determinants of sex hormone-binding globulin concentrations in a cross-sectional study of healthy men randomly selected. *J Nutr Health Aging*. 2007 Jan-Feb;11(1):60-4. PubMed PMID:17315082.
17. Chapurlat RD, Bauer DC, Cummings SR. Association between endogenous hormones and sex hormone-binding globulin and bone turnover in older women: study of osteoporotic fractures. *Bone*. 2001 Oct;29(4):381-7. PMID: 11595622.
18. Dempster DW, Cosman F, Parisien M, Shen V, Lindsay R. Anabolic actions of parathyroid hormone on bone. *Endocr Rev*. 1993 Dec;14(6):690-709. Review. Erratum in: *Endocr Rev* 1994 Apr;15(2):261. PubMed PMID: 8119233.
19. Johansson AG, Baylink DJ, af Ekenstam E, Lindh E, Mohan S, Ljunghall S. Circulating levels of insulin-like growth factor-I and -II, and IGF-binding protein-3 in inflammation and after parathyroid hormone infusion. *Bone Miner*. 1994 Jan;24(1):25-31. PMID: 7514466.
20. Divieti P, Inomata N, Chapin K, Singh R, Jüppner H, Brighurst FR. Receptors for the carboxyl-terminal region of pth(1-84) are highly expressed in osteocytic cells. *Endocrinology*. 2001 Feb;142(2):916-25. PMID: 11159865.
21. Glover SJ, Eastell R, McCloskey EV, Rogers A, Gamero P, Lowery J, Belleli R, Wright TM, John MR. Rapid and robust response of biochemical markers of bone formation to teriparatide therapy. *Bone*. 2009 Dec;45(6):1053-8. Epub 2009 Aug 11. PMID: 19679211.
22. Lau AN, Ali SH, Sawka AM, Thabane L, Papaioannou A, Gafni A, Adachi JD. Improvement in health-related quality of life in osteoporosis patients treated with teriparatide. *BMC Musculoskelet Disord*. 2008 Nov 7;9:151. PMID: 18990249.
23. Panico A, Lupoli GA, Marciello F, Lupoli R, Cacciapuoti M, Martinelli A, Granieri L, Iacono D, Lupoli G. Teriparatide vs. alendronate as a treatment for osteoporosis: changes in biochemical markers of bone turnover, BMD and quality of life. *Med Sci Monit*. 2011 Aug;17(8):CR442-448. PMID: 21804463.
24. Maugeri D, Russo E, Luca S, Leotta C, Mamazza G, Sorace R, Rizzotto M, Manuele S, Fiore V, Taverna G, Castiglia B, Calitro M. Changes of the quality-of-life under the treatment of severe senile osteoporosis with teriparatide. *Arch Gerontol Geriatr*. 2009 Jul-Aug; 49(1): 35-8. Epub 2008 Jun 13. PMID: 18555544.
25. Manuele S, Sorbello L, Puglisi N, Grasso S, La Malfa L, D'Urbino G, Rizzotto M, Strano S, Maugeri D. The teriparatide in the treatment of severe senile osteoporosis. *Arch Gerontol Geriatr*. 2007; 44 Suppl 1: 249-58. PMID: 17317460.

Appendix 1:

OSTEOPOROSIS EVALUATION FORM:

Date:

Phone:

Name/Family Name:

Gender: F M

Age:

Education level:

Body weight:

Height:

BMI:

Menarche age:

Number of parturition:

Pregnancy period:

Lactation period:

Age and duration of menopause:...../.....

Hysterectomy or Ovaryectomy:

Comorbid Illnesses:

Inactive - Sedentary life: No Yes

Family history for fractures: : No Yes

Chronic use of medications and durations of therapy Rheumatology International pills:

Alcohol:

Smoking:

Coffee:

Calcium Intake: Milk (1glass/day):

 Yogurt (1 cup/day):

 Cheese (1slice/gün):

 Fish (1 serving/week):

 Other: red meat:

Appendix-2

QUALEFFO-41 *Quality of life questionnaire*

A- PAIN

The five questions in this section regard your situation in the last week.

- 1) How often have you had back pain in the last week?
 - A) none
 - B) 1 day per week or less
 - C) 2-3 days per week
 - D) 4-6 days per week
 - E) every day
- 2) If you have had back pain, for how long did your back pain last during daytime?
 - A) none B) 1-2 hours C) 3-5 hours
 - D) 6-10 hours E) all day
- 3) How severe is your back pain at its worst?
 - A) no back pain B) mild C) moderate D) severe E) unbearable
- 4) How is your back pain at other times?
 - A) no back pain B) mild C) moderate
 - D) severe E) unbearable
- 5) Has the back pain disturbed your sleep in the last week?
 - A) less than once per week
 - B) once a week
 - C) twice a week
 - D) every other night
 - E) every night

B- PHYSICAL FUNCTIONS: ACTIVITIES OF DAILY LIVING

The next 4 questions regard your situation at present.

- 6) Do you have problems with dressing?
 - A) no difficulty
 - B) a little difficulty
 - C) moderate difficulty
 - D) may need some help
 - E) impossible without help

- 7) Do you have problems when bathing or taking a shower?
 - A) no difficulty
 - B) a little difficulty
 - C) moderate difficulty
 - D) may need some help
 - E) impossible without help
- 8) Do you have problems with getting to or using the toilet?
 - A) no difficulty
 - B) a little difficulty
 - C) moderate difficulty
 - D) may need some help
 - E) impossible without help
- 9) How well do you sleep?
 - A) sleep undisturbed
 - B) wake up sometimes
 - C) wake up often
 - D) sometimes I lie awake for hours
 - E) sometimes I have a sleepless night

C-PHYSICAL FUNCTIONS: HOUSEHOLD CHORES

The next 5 questions are concerned with the present situation. If someone else performs these tasks in your house, please answer as though you were responsible for them.

- 10) Can you do the cleaning?
 - A) without difficulty
 - B) with a little difficulty
 - C) with moderate difficulty
 - D) with great difficulty
 - E) impossible
- 11) Can you prepare meals?
 - A) without difficulty
 - B) with a little difficulty
 - C) with moderate difficulty
 - D) with great difficulty
 - E) impossible

- 12) Can you wash the dishes?
 A) without difficulty
 B) with a little difficulty
 C) with moderate difficulty
 D) with great difficulty
 E) impossible
- 13) Can you do your day to day shopping?
 A) without difficulty
 B) with a little difficulty
 C) with moderate difficulty
 D) with great difficulty
 E) impossible
- 14) Can you lift a heavy object weighing about 9 kg (eg., a case of milk bottles or a one-year old child) and carry for at least 9 meters?
 A) without difficulty
 B) with a little difficulty
 C) with moderate difficulty
 D) with great difficulty
 E) impossible
- 19) Can you walk 90 meters?
 A) fast without stopping
 B) slowly without stopping
 C) slowly with at least one stop
 D) only with help
 E) impossible
- 20) How often have you been outside in the last week?
 A) every day
 B) 5-6 days per week
 C) 3-4 days per week
 D) 1-2 days per week
 E) less than once a week
- 21) Can you use public transportation?
 A) without difficulty
 B) with a little difficulty
 C) with moderate difficulty
 D) with great difficulty
 E) only with help
- 22) Have you been affected by the changes to your figure due to osteoporosis (for example, loss of height, increase in waist circumference, shape of your back)?
 A) not at all
 B) a little
 C) moderately
 D) quite a bit
 E) very much

D- PHYSICAL FUNCTIONS: MOBILITY

The next 8 questions regard your present situation.

- 15) Can you get up from a chair?
 A) without difficulty
 B) with a little difficulty
 C) with moderate difficulty
 D) with great difficulty
 E) only with help
- 16) Can you lean forward?
 A) easily
 B) fairly easily
 C) moderately
 D) very little
 E) impossible
- 17) Can you kneel down?
 A) easily
 B) fairly easily
 C) moderately
 D) very little
 E) impossible
- 18) Can you climb upstairs to the next floor of a house?
 A) without difficulty
 B) with a little difficulty
 C) with at least one rest
 D) only with help
 E) impossible
- 23) Do you do any support currently?
 A) yes
 B) yes but with some restrictions
 C) not at all
- 24) Can you do your gardening?
 A) yes
 B) yes but with some restrictions
 C) not at all
 D) I do not have a garden
- 25) Do you have any hobbies currently?
 A) yes
 B) yes but with some restrictions
 C) not at all
- 26) Can you go to places like a cinema or theater?
 A) yes
 B) yes but with some restrictions
 C) not at all
 D) no cinema or theater within my neighbourhood

- 27) How often did you visit your friends or relatives during the last 3 months?
 A) once a week or more
 B) once or twice a month
 C) less than once a month
 D) none
- 28) How often did you participate in social activities (clubs, social gatherings, religious activities, charity) during the last 3 months?
 A) once a week or more
 B) once or twice a month
 C) less than once a month
 D) never
- 29) Does your back pain or disability interfere with your intimacy (including sexual activity)?
 A) not at all
 B) a little
 C) moderately
 D) severely
 E) not applicable

F- GENERAL HEALTH EVALUATION

- 30) For your age, in general, would you say your health is ...
 A) excellent
 B) good
 C) satisfactory
 D) fair
 E) poor
- 31) How would you rate your overall quality of life during the last week?
 A) excellent
 B) good
 C) satisfactory
 D) fair
 E) poor
- 32) How would you rate your overall quality of life compared with 10 years ago?
 A) much better now
 B) slightly better now
 C) unchanged
 D) slightly worse now
 E) much worse now

G-MENTAL FUNCTIONS

Think of your condition during the last week when answering the next 9 months.

- 33) Do you tend to feel tired?
 A) in the morning
 B) in the afternoon
 C) only in the evening
 D) after strenuous activity
 E) almost never
- 34) Do you feel downhearted?
 A) almost every day
 B) 3-5 days a week
 C) 1-2 days a week
 D) once in a while
 E) almost never
- 35) Do you feel lonely?
 A) almost every day
 B) 3-5 days a week
 C) 1-2 days a week
 D) once in a while
 E) almost never
- 36) Do you feel full of energy?
 A) almost every day
 B) 3-5 days a week
 C) 1-2 days a week
 D) once in a while
 E) almost never
- 37) Are you hopeful about your future?
 A) never
 B) rarely
 C) sometimes
 D) quite often
 E) always
- 38) Do you get upset over little matters?
 A) never
 B) rarely
 C) sometimes
 D) quite often
 E) always
- 39) Do you find it easy to make contact with people?
 A) never
 B) rarely
 C) sometimes
 D) quite often
 E) always

40) Are you in good spirits most of the day?

- A) never
- B) rarely
- C) sometimes
- D) quite often
- E) always

41) Are you afraid of becoming totally dependent?

- A) never
- B) rarely
- C) sometimes
- D) quite often
- E) always

İLETİŐİM

Ece HARMAN, MD

Email: ecarmu@gmail.com

Mobile phone: +90 537 254 53 28

Izmir Ataturk Training and Research Hospital,
Department of Endocrinology, Izmir, Turkey


Journals Master List 2007	Editorial office address	İzmir tepecik eđit Arařt Hastn 1.Cerrahi Kliniđi 35120 İzmir Gaziler Cad 468 Turkey
Journals Master List 2006		
Journals Master List 2005	Editor in Chief	Ragıp KAYAR E-mail: ragip_kayar@yahoo.com Telefon: 90-533-7168511
	Executive Editor	İbrahim ÇUKUROVA E-mail: cukurova57@gmail.com Telefon: 90-532-2821133
	Published by	META Basım Matbaacılık Hizmetleri 35040 İzmir 87 Sok.No.4/B Bornova Turkey E-mail: metabasim@gmail.com Telefon: 90-232-3427524

Extended Section | Scientific profile

Character of the publications	Scientific
Scientific disciplines	Medicine Journal indexation
ISI Journal Master List	No
Science Citation Index Expanded	No
BIOBASE	No
Chemical Abstracts CAS	No
ERIH	No
Scopus	No
Current Contents	No
Index Medicus/MEDLINE	No
EMBASE/Excerpta Medica	No
other indexes	Turkish Medical Index ULAKBİM; Tubitak/Ulakbim ;

Wszelkie prawa zastrzeżone przez

[Index Copernicus sp. z o.o.](#)



Current language: English

Login:

Password:

Sign in

Register



IC Journals Master List

[Journal of the Week](#)
[Journals Master List](#)
[Recently Added Journals](#)
[Top 100 Journals](#)
[Publishers](#)
[Top 20 Publishers](#)
[Journal Search](#)
[Article Search](#)
[Evaluation methodology](#)
[FAQ](#)
[Contact](#)

IC Conferences

[Conferences](#)

IC Journals Master List 2011

[Journals Master List 2011](#)

Submission Menu

[Register Journal](#)
[- Free Service](#)
[IC Publisher Panel](#)

Archives

[Journals Master List 2010](#)
[Journals Master List 2009](#)
[Journals Master List 2008](#)

IndexCopernicus Journal Information

Basic Section

Main title [Turkish]	İzmir Tepecik Eğitim Hastanesi Dergisi
Other title [English]	The Journal of Tepecik Teaching Hospital
p-ISSN	1305-7073
e-ISSN	1305-7146
URL	http://www.tepecikhastanesi.gov.tr
Country	Turkey
Affiliation	İzmir Tepecik Eğitim ve Araştırma Hastanesi
Frequency	Quarterly
Insert to IC	2010-09-23
Year publication	1991
Year publication electronic	2010
Editor in Chief	Ragıp KAYAR
Executive Editor	İbrahim ÇUKUROVA
Fulltext language	Turkish
Abstract language	English
Published by	META Basım Matbaacılık Hizmetleri
Journal description [English]	Although one third of articles come from exterior hospitals,mainly authors from our institution,which is a 1000 bed Research and Teaching hospital submit their original articles.No spesific field of medicine has been excluded.All disciplines of medicine were included to the journal.So it is a journal of general medicine.Main purpose is to publish regularly and so that original articles must exceed case reports and reviews in number.As an editorial policy we consider negative opinions and give extra-discussion chance to peer reviewers.Sometimes we publish them as well,if they are contributable to the readers.
Journal description [Turkish]	başvuruların üçtebiri dış merkezlerden olmakla birlikte çoğu orjinal araştırma 1000 yataklı bir eğitim ve araştırma hastanesi olan kendi kurumumuzdan gelir.Branş ayrımı olmadığı için genel tıp dergisiolarak kabul edilmelidir.Amacımız düzenli çıkmak ve orjinal makale sayısını çoğunlukta tutmaktır.Zit görüşlere ek tartışma yayınlayarak destek vermekteyiz

Extended Section | IC Value

IC Value 2011	not indexed
Current status 2012	Evaluation pending
ICV history	no historical data

Extended Section | Contacts and Addresses